Eupraxia Pharmaceuticals Inc. (OTCMKTS:EPRXF – Get Free Report) rose 1.7% during trading on Friday . The stock traded as high as C$3.09 and last traded at C$3.05. Approximately 1,431 shares traded hands during mid-day trading, a decline of 81% from the average daily volume of 7,410 shares. The stock had previously closed at C$3.00.
Eupraxia Pharmaceuticals Stock Down 1.0 %
The business’s 50 day moving average is C$3.20 and its 200-day moving average is C$2.81.
Eupraxia Pharmaceuticals Company Profile
Eupraxia Pharmaceuticals Inc, a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidate is EP-104IAR, which is in a Phase II clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis and eosinophilic esophagitis, as well as under development for treating canine osteoarthritis.
Further Reading
- Five stocks we like better than Eupraxia Pharmaceuticals
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- ServiceTitan Made Waves in Its IPO, But Is the Stock a Buy?
- Find and Profitably Trade Stocks at 52-Week Lows
- Netflix: Is This the Perfect Time to Buy a Streaming Powerhouse?
- How to Use the MarketBeat Excel Dividend Calculator
- Goldman Sachs Unveils 3 Massive Opportunities for 2025 Investors
Receive News & Ratings for Eupraxia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eupraxia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
